60 Degrees Pharmaceuticals, Inc. (SXTP)

NCM – Цена в реальном времени. Валюта: USD

1.61

-0.03 (-1.83%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

1.61

0.00 (0.00%)

После закрытия: Jun 26, 2026, 4:10 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

60 Degrees Pharmaceuticals, Inc. (SXTP)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

60 Degrees Pharmaceuticals, Inc. (SXTP)

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know

60 Degrees Pharmaceuticals Announces 2025 Annual Results

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

What's Going On With 60 Degrees Pharmaceuticals On Friday?

Видео

No Data

Пресс-релизы

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

60 Degrees Pharmaceuticals Announces 2025 Annual Results

Search stocks

60 Degrees Pharmaceuticals, Inc. (SXTP)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

60 Degrees Pharmaceuticals, Inc. (SXTP)

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know

60 Degrees Pharmaceuticals Announces 2025 Annual Results

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

What's Going On With 60 Degrees Pharmaceuticals On Friday?

Видео

No Data

Пресс-релизы

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

60 Degrees Pharmaceuticals Announces 2025 Annual Results